Complete Regression of 11 Hepatic Metastases in Metastatic Pancreatic Adenosquamous Carcinoma and the Role of GPT in Patient Navigation.

Int Med Case Rep JOct 3, 2026 (epub)
Case ReportOncology (Medical)Radiology (Diagnostic)Open access

Suleyman T Khalil

✦ AI-curated · Sources linked

Case in brief

A 65-year-old man with resected pancreatic adenosquamous carcinoma (pT3 pN2, R0) had 11 liver lesions interpreted as metastases on MRI. He began FOLFIRINOX, with patient- and author-added off-label home measures that the report does not claim were effective. MRI after three cycles showed complete radiological regression, confirmed around cycle six; chemotherapy was stopped after six cycles. Later cholestasis and a CA 19-9 rise raised concern for recurrence, but the marker fell after ursodeoxycholic acid and normalized. Follow-up MRI showed no visible hepatic lesions.

What made this case unusual

The report describes complete radiological regression of 11 presumed hepatic metastases in metastatic pancreatic adenosquamous carcinoma, while emphasizing that CA 19-9 elevation during cholestasis can complicate assessment for recurrence.

Diagnostic / clinical pearl

Interpret CA 19-9 cautiously in the setting of cholestasis: in this case, the rise resolved as cholestasis was treated, and follow-up MRI showed no visible hepatic lesions.

Source

PubMed · PMID 42846516Free full text on PubMed Central

Published in Int Med Case Rep J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.